Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Files An 8-K Regulation FD Disclosure

ME Staff 8-k
-
0

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Files An 8-K Regulation FD Disclosure
Item 7.01Regulation FD Disclosure.

On October 4, 2017, Aclaris Therapeutics, Inc. (the “Company”) will host an R&D and Investor Event in New York, New York, and a live webcast of the event will be available through the Events and Presentations page of the Investors section of the Company’s website. The R&D and Investor Event will include a slide presentation.A copy of this slide presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information set forth in this Item 7.01 and contained in the presentation furnished as Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is not incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits

Exhibit

Number

ExhibitDescription

99.1

Company Presentation


Aclaris Therapeutics, Inc. Exhibit
EX-99.1 2 ex-99d1.htm EX-99.1 acrs_Ex99_1 Exhibit 99.1   Aclaris Therapeutics R&D and Investor Day October 4,…
To view the full exhibit click here

About Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

Aclaris Therapeutics, Inc. is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to address the needs in dermatology. Its lead drug candidate, A-101 Topical Solution, is a hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis (SK). It has completed approximately three Phase II clinical trials of A-101. It has initiated over two multi-center, double blind Phase III clinical trials and an open label Phase III clinical trial of A-101 in patients with SK. It also intends to develop A-101 as a prescription treatment for common warts, also known as verruca vulgaris, and A-102, a gel dosage form of hydrogen peroxide, as a prescription treatment for SK and common warts. It has initiated a Phase II clinical trial to evaluate A-101 for the treatment of common warts.